Your browser is no longer supported. Please, upgrade your browser.
EQ [NASD]
Equillium, Inc.
Index- P/E- EPS (ttm)-1.48 Insider Own3.80% Shs Outstand24.77M Perf Week-14.58%
Market Cap156.47M Forward P/E- EPS next Y-1.61 Insider Trans-2.94% Shs Float18.11M Perf Month-22.03%
Income-29.80M PEG- EPS next Q-0.32 Inst Own30.60% Short Float5.19% Perf Quarter-41.59%
Sales- P/S- EPS this Y0.60% Inst Trans13.96% Short Ratio3.22 Perf Half Y11.45%
Book/sh2.82 P/B1.93 EPS next Y-16.70% ROA-43.80% Target Price- Perf Year64.65%
Cash/sh2.86 P/C1.90 EPS next 5Y- ROE-55.40% 52W Range2.53 - 27.05 Perf YTD1.87%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-80.11% Beta-
Dividend %- Quick Ratio11.80 Sales past 5Y- Gross Margin- 52W Low112.65% ATR0.45
Employees31 Current Ratio11.80 Sales Q/Q- Oper. Margin- RSI (14)32.76 Volatility6.24% 7.44%
OptionableYes Debt/Eq0.14 EPS Q/Q17.30% Profit Margin- Rel Volume0.50 Prev Close5.45
ShortableYes LT Debt/Eq0.12 Earnings- Payout- Avg Volume291.63K Price5.38
Recom1.40 SMA20-13.70% SMA50-21.60% SMA200-17.45% Volume129,541 Change-1.28%
Jul-14-20Reiterated H.C. Wainwright Buy $14 → $24
Jul-10-20Resumed Stifel Buy $22 → $10
Feb-22-19Initiated SVB Leerink Outperform $16
Apr-27-21 08:00AM  
Mar-31-21 07:44AM  
07:37AM  
Mar-30-21 04:01PM  
Mar-24-21 04:05PM  
Mar-15-21 08:00AM  
Mar-03-21 10:02AM  
Mar-02-21 08:00AM  
Feb-18-21 08:00AM  
Feb-12-21 03:00PM  
Feb-09-21 08:00AM  
Feb-07-21 03:16AM  
Feb-05-21 05:36PM  
Feb-04-21 08:00AM  
Jan-22-21 08:00AM  
Jan-05-21 08:00AM  
Dec-29-20 11:27AM  
Dec-21-20 08:00AM  
Dec-07-20 08:00AM  
Nov-30-20 09:30PM  
08:00AM  
Nov-26-20 10:24AM  
Nov-25-20 08:46AM  
08:00AM  
Nov-10-20 04:05PM  
08:35AM  
Nov-06-20 08:35AM  
Nov-04-20 08:35AM  
Oct-29-20 04:13PM  
Oct-13-20 11:30AM  
Sep-17-20 04:07PM  
Sep-15-20 08:07AM  
Sep-03-20 04:07PM  
Aug-18-20 04:05PM  
Aug-13-20 09:42PM  
04:02PM  
Aug-12-20 08:37AM  
Aug-11-20 08:20AM  
08:00AM  
07:51AM  
Aug-10-20 04:07PM  
Jul-30-20 04:07PM  
Jul-14-20 11:47AM  
10:54AM  
Jul-13-20 07:33AM  
03:30AM  
Jun-03-20 09:00AM  
May-21-20 04:07PM  
May-13-20 04:07PM  
May-07-20 04:07PM  
Mar-30-20 04:07PM  
Mar-26-20 04:07PM  
Feb-27-20 04:14PM  
Feb-13-20 04:07PM  
Jan-29-20 04:07PM  
Jan-28-20 07:33AM  
Jan-09-20 10:01AM  
Jan-03-20 09:52AM  
Dec-22-19 06:41PM  
Dec-12-19 07:00AM  
Dec-10-19 07:56AM  
Dec-09-19 04:10PM  
07:13AM  
Nov-26-19 04:07PM  
Nov-15-19 08:05AM  
Nov-12-19 04:07PM  
04:05PM  
Nov-07-19 04:07PM  
Nov-06-19 08:05AM  
Oct-31-19 09:14AM  
Oct-01-19 04:05PM  
Sep-19-19 11:51AM  
Sep-17-19 04:07PM  
Aug-27-19 04:07PM  
Aug-12-19 04:07PM  
Jul-10-19 08:07AM  
May-23-19 04:07PM  
May-13-19 04:07PM  
May-06-19 08:30AM  
Apr-16-19 04:07PM  
Mar-28-19 04:07PM  
Mar-27-19 04:07PM  
Feb-26-19 04:07PM  
Feb-21-19 04:07PM  
Feb-19-19 04:07PM  
Feb-07-19 08:08AM  
Dec-19-18 08:06AM  
Nov-15-18 04:07PM  
Nov-01-18 04:07PM  
Oct-12-18 08:25AM  
07:24AM  
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Connelly StephenChief Scientific OfficerDec 28Sale4.5225,000113,045993,000Dec 30 05:00 PM
Keyes Jason AChief Financial OfficerDec 23Sale4.748,00037,914120,720Dec 28 09:15 AM
Connelly StephenChief Scientific OfficerSep 28Sale5.6225,000140,3951,018,000Sep 30 05:00 PM
Connelly StephenChief Scientific OfficerJul 13Sale8.13250,0002,033,4751,043,000Jul 15 05:00 PM